Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223 / Mónica Alexandra Vidal González ; Alejandro Delgado Quijano ; Carlos Humberto Martínez González ; José Jaime Correa Ochoa ; Isabel Cristina Durango    

Público ISBD Título : Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223 Tipo de documento : documento electrónico Autores : Mónica Alexandra Vidal González, ; Alejandro Delgado Quijano, ; Carlos Humberto Martínez González, ; José Jaime Correa Ochoa, ; Isabel Cristina Durango, Fecha de publicación : 2020 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Castration  Prostatic Neoplasms  Radium-223 [Supplementary Concept] Resumen : Objective: Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). Objectives: The aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was to identify the factors that can predict a better response to treatment and provide information regarding the most appropriate time for the application of 223Ra. Materials and methods: Prospective study in 40p with mCRPC treated with 223Ra. End points were OS, progression-free survival and time to progression. The follow-up parameters were: doses received, hemoglobin (Hb), absolute neutrophil count (ANC), platelet count (PC), prostate specific antigen (PSA), alkaline phosphatase (ALP), Visual Analogue Scale for pain, Eastern Cooperative Oncology Group (ECOG) and WHO's Cancer Pain Ladder. The use of other treatments was also evaluated. Results: Median OS was 17.1 months(mo) (CI95%6.5-27.7); 26/40p received complete treatment of 223Ra, without reaching a median OS and 14p received incomplete treatment with a median OS 13.6mo(CI95%1.6-25.6). Median follow-up was 11.2mo (range:1.3-45.2). The univariate analysis showed that factors as VAS, ECOG, Hb and ALP values were independently associated with OS. First line treatment with 223Ra was started in 11/40p, while 19p had been heavily pre-treated and 13p received concomitant treatment. Conclusions: 223Ra therapy require an adequate selection of patients to obtain the greatest clinical benefit. Low basal Hb, hight basal ALP, bone marrow involvement and an altered ECOG were the main factors that decreased OS in our patients. 223Ra should be considered relatively early in the course of treatment. Mención de responsabilidad : Monica Vidal, Alejandro Delgado, Carlos Martinez, José Jaime Correa, Isabel Cristina Durango Referencia : Int Braz J Urol. Jul-Aug 2020;46(4):599-611. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2019.0343 PMID : 32213206 Derechos de uso : CC BY En línea : https://www.intbrazjurol.com.br/pdf/aop/2019-0343OA.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5096 Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223 [documento electrónico] / Mónica Alexandra Vidal González, ; Alejandro Delgado Quijano, ; Carlos Humberto Martínez González, ; José Jaime Correa Ochoa, ; Isabel Cristina Durango,  . - 2020. Obra : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Castration  Prostatic Neoplasms  Radium-223 [Supplementary Concept] Resumen : Objective: Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). Objectives: The aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was to identify the factors that can predict a better response to treatment and provide information regarding the most appropriate time for the application of 223Ra. Materials and methods: Prospective study in 40p with mCRPC treated with 223Ra. End points were OS, progression-free survival and time to progression. The follow-up parameters were: doses received, hemoglobin (Hb), absolute neutrophil count (ANC), platelet count (PC), prostate specific antigen (PSA), alkaline phosphatase (ALP), Visual Analogue Scale for pain, Eastern Cooperative Oncology Group (ECOG) and WHO's Cancer Pain Ladder. The use of other treatments was also evaluated. Results: Median OS was 17.1 months(mo) (CI95%6.5-27.7); 26/40p received complete treatment of 223Ra, without reaching a median OS and 14p received incomplete treatment with a median OS 13.6mo(CI95%1.6-25.6). Median follow-up was 11.2mo (range:1.3-45.2). The univariate analysis showed that factors as VAS, ECOG, Hb and ALP values were independently associated with OS. First line treatment with 223Ra was started in 11/40p, while 19p had been heavily pre-treated and 13p received concomitant treatment. Conclusions: 223Ra therapy require an adequate selection of patients to obtain the greatest clinical benefit. Low basal Hb, hight basal ALP, bone marrow involvement and an altered ECOG were the main factors that decreased OS in our patients. 223Ra should be considered relatively early in the course of treatment. Mención de responsabilidad : Monica Vidal, Alejandro Delgado, Carlos Martinez, José Jaime Correa, Isabel Cristina Durango Referencia : Int Braz J Urol. Jul-Aug 2020;46(4):599-611. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2019.0343 PMID : 32213206 Derechos de uso : CC BY En línea : https://www.intbrazjurol.com.br/pdf/aop/2019-0343OA.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5096

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001326	AC-2020-030	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2020-030.pdf Adobe Acrobat PDF

Synchronous and multiple renal cell carcinoma, clear cell and papillary: an approach to clinically significant genetic abnormalities / Carlos Humberto Martínez González    

Público ISBD Título : Synchronous and multiple renal cell carcinoma, clear cell and papillary: an approach to clinically significant genetic abnormalities Tipo de documento : documento electrónico Autores : Carlos Humberto Martínez González, Fecha de publicación : 2020 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Mención de responsabilidad : Laura Cifuentes-C, Carlos Humberto Martinez, Herney Andres Garcia-Perdomo Referencia : Int Braz J Urol. 2020;46(2):287–293. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2019.0015 PMID : 32022527 Derechos de uso : CC BY En línea : https://www.intbrazjurol.com.br/pdf/vol46n02/Cifuentes-C_287_293.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5067 Synchronous and multiple renal cell carcinoma, clear cell and papillary: an approach to clinically significant genetic abnormalities [documento electrónico] / Carlos Humberto Martínez González,  . - 2020. Obra : International Brazilian Journal of Urology Idioma : Inglés (eng) Mención de responsabilidad : Laura Cifuentes-C, Carlos Humberto Martinez, Herney Andres Garcia-Perdomo Referencia : Int Braz J Urol. 2020;46(2):287–293. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2019.0015 PMID : 32022527 Derechos de uso : CC BY En línea : https://www.intbrazjurol.com.br/pdf/vol46n02/Cifuentes-C_287_293.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5067

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001297	AC-2020-001	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2020-001.pdf Adobe Acrobat PDF

Editorial Comment: Urologic surgery laparoscopic access: vascular complications / José Jaime Correa Ochoa    

Público ISBD Título : Editorial Comment: Urologic surgery laparoscopic access: vascular complications Tipo de documento : documento electrónico Autores : José Jaime Correa Ochoa, Fecha de publicación : 2017 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Mención de responsabilidad : Jose Jaime Correa Referencia : Int Braz J Urol. 2017 Jan-Feb;43(1):168. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0369.2 PMID : 28124543 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382017000100168&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4023 Editorial Comment: Urologic surgery laparoscopic access: vascular complications [documento electrónico] / José Jaime Correa Ochoa,  . - 2017. Obra : International Brazilian Journal of Urology Idioma : Inglés (eng) Mención de responsabilidad : Jose Jaime Correa Referencia : Int Braz J Urol. 2017 Jan-Feb;43(1):168. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0369.2 PMID : 28124543 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382017000100168&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4023

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000618	AC-2017-007	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2017-007.pdf Adobe Acrobat PDF

Overactive bladder - 18 years - Part I / Juan Carlos Castaño Botero    

Público ISBD Título : Overactive bladder - 18 years - Part I Tipo de documento : documento electrónico Autores : Juan Carlos Castaño Botero, Fecha de publicación : 2016 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder  Muscarinic Antagonists  Beta-adrenergic agonists  Botulinum Toxin  Sacral neuromodulation  Urodynamics Resumen : Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0365 PMID : 27176184 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3981 Overactive bladder - 18 years - Part I [documento electrónico] / Juan Carlos Castaño Botero,  . - 2016. Obra : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder  Muscarinic Antagonists  Beta-adrenergic agonists  Botulinum Toxin  Sacral neuromodulation  Urodynamics Resumen : Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals – including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0365 PMID : 27176184 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200188&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3981

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000573	AC-2016-048	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2016-048.pdf Adobe Acrobat PDF

Overactive bladder - 18 years - Part II / Juan Carlos Castaño Botero    

Público ISBD Título : Overactive bladder - 18 years - Part II Tipo de documento : documento electrónico Autores : Juan Carlos Castaño Botero, Fecha de publicación : 2016 Títulos uniformes : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder  Muscarinic Antagonists  Beta-adrenergic agonists  Botulinum Toxin  Sacral neuromodulation  Urodynamics Resumen : Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0367 PMID : 27176185 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980 Overactive bladder - 18 years - Part II [documento electrónico] / Juan Carlos Castaño Botero,  . - 2016. Obra : International Brazilian Journal of Urology Idioma : Inglés (eng) Palabras clave : Overactive Bladder  Muscarinic Antagonists  Beta-adrenergic agonists  Botulinum Toxin  Sacral neuromodulation  Urodynamics Resumen : Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder. Mención de responsabilidad : Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell'Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, Jose Antonio Garcia, Juan Castano, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda Lopez, Ricardo Reges Referencia : Int Braz J Urol. 2016 Mar-Apr;42(2):199-214. DOI (Digital Object Identifier) : 10.1590/S1677-5538.IBJU.2015.0367 PMID : 27176185 Derechos de uso : CC BY En línea : http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000200199&l [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3980

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000572	AC-2016-047	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2016-047.pdf Adobe Acrobat PDF

Editorial comment / José Jaime Correa Ochoa    

Permalink

Editorial comment / José Jaime Correa Ochoa  

Permalink

Editorial Comment / José Jaime Correa Ochoa    

Permalink

Editorial comment / José Jaime Correa Ochoa    

Permalink

Editorial comment / José Jaime Correa Ochoa    

Permalink

---

1 (1 - 10 / 10) Por página: 25 50 100 200